Oil Refineries Updates on Gadot Biotechnologies Tender Offer

* Reuters is not responsible for the content in this press release.

Tue Jun 30, 2009 2:54pm EDT

HAIFA, Israel, June 30 /PRNewswire-FirstCall/ -- Oil Refineries Ltd.
(TASE: ORL.TA) (the "Company"), Israel's largest oil refiner, announced that
the tender offer announced May 27, 2009 by the Company and Delek Investment
and Assets Ltd. for the acquisition of the outstanding share capital of Gadot
Biotechnologies has not been completed given that the minimum required
acceptance level was not met. Subsequently, Gadot remains a public company
listed on the Tel Aviv Stock Exchange.
    About Oil Refineries Ltd.
    Oil Refineries Ltd. (ORL), located in the bay area of the city of Haifa,
is Israel's largest oil refinery. ORL operates sophisticated and
state-of-the-art industrial facilities with refining capacity of 9 million
tons of crude oil per year, with a Nelson complexity index of 7.4, providing
a variety of quality products used in industrial operation, transportation,
private consumption, agriculture and infrastructure. The Company is also
active in the area of Aromatics and Polymers through wholly-owned Gadiv
Petrochemical Industries Ltd. and 50% owned Carmel Olefins Ltd. ORL is traded
on the Tel Aviv Stock Exchange under the ticker ORL. For additional
information please visit the Company's website: http://www.orl.co.il
    Contacts:

    Company Contact:
    Rony Solonicof, Chief Economist and Head of Investor Relations
    Oil Refineries
    Tel: +972-4-878-8320
    ContactIREn@orl.co.il

    Investor Relations Contact:
    Ehud Helft / Fiona Darmon
    GK Investor Relations
    Tel: +1-646-797-2868 / +972-52-695-4400
    info@gkir.com


SOURCE  Oil Refineries Ltd

Contacts: Company Contact: Rony Solonicof, Chief Economist and Head of
Investor Relations, Oil Refineries, Tel: +972-4-878-8320,
ContactIREn@orl.co.il; Investor Relations Contact: Ehud Helft / Fiona Darmon,
GK Investor Relations, Tel: +1-646-797-2868 / +972-52-695-4400, info@gkir.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.